Originally published as JCO Early Release 10.1200/JCO.2006.08.1604 on May 7 2007

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vardy, J. Articles by Tannock, I. F. Search for Related Content PubMed PubMed Citation Articles by Vardy, J. Articles by Tannock, I. F. Social Bookmarking                            What's this?

Evaluation of Cognitive Function Associated With Chemotherapy: A Review of Published Studies and Recommendations for Future Research

Janette Vardy, Sean Rourke, Ian F. Tannock

From the Princess Margaret Hospital; and St Michael's Hospital, Toronto, Ontario, Canada

Address reprint requests to Ian Tannock, MD, PhD, FRCPC, Princess Margaret Hospital, Department of Medical Oncology, 610 University Ave, Toronto, ON M5G 2M9, Canada; e-mail: Ian.Tannock{at}uhn.on.ca

Purpose There is evidence that some cancer survivors suffer cognitive impairment after chemotherapy. Determining if a patient has cognitive impairment is challenging, especially because impairment is usually subtle.

Patients and Methods We assessed the design of studies evaluating cognitive function during or after chemotherapy in adult patients with solid tumors. We also reviewed methods used to evaluate cognitive function in subjects with other diseases and make recommendations for future studies.

Results We identified 22 studies that met our criteria: 82% included women with breast cancer. Eight studies were longitudinal, 12 were cross-sectional, and two were follow-ups of cross-sectional studies. Sixteen studies used a battery of neuropsychological (NP) tests to assess subjects, and 13 included a control group. Ten studies (45%) had no explicit definition of cognitive impairment; most others used z scores or T scores and defined impairment based on standard deviations below the mean, but there was no consistency in for the cutoff point used or the number of tests required.

Conclusion There is no consistency in defining cognitive impairment, in the NP batteries used, or in statistical methods in studies of cognitive function of cancer patients. We suggest guidelines to define criteria for cognitive impairment. Use of summary scores and control groups is recommended. Practice effect should be adjusted for in longitudinal studies. A balance is needed between comprehensive batteries and briefer tests, which still need to be sensitive to mild impairment.

published online ahead of print at www.jco.org on May 7, 2007.

Supported by grants from the National Cancer Institute of Canada and the Susan G. Komen Foundation, and by an ASCO Young Investigator Award (J.V.).

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				N. Barahmani, S. Carpentieri, X.-N. Li, T. Wang, Y. Cao, L. Howe, L. Kilburn, M. Chintagumpala, C. Lau, and M. F. Okcu Glutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastoma Neuro-oncol, January 1, 2009; 11(3): 292 - 300. [Abstract] [Full Text] [PDF]

				J. Vardy Cognitive Function in Survivors of Cancer ASCO Educational Book, January 1, 2009; 2009(1): 570 - 574. [Abstract] [Full Text] [PDF]

				J. Vardy, J. S. Wefel, T. Ahles, I. F. Tannock, and S. B. Schagen Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop Ann. Onc., April 1, 2008; 19(4): 623 - 629. [Abstract] [Full Text] [PDF]

				J. E. Bower Behavioral Symptoms in Patients With Breast Cancer and Survivors J. Clin. Oncol., February 10, 2008; 26(5): 768 - 777. [Abstract] [Full Text] [PDF]